Rachel E Ashley, Tim R Blower1, James M Berger1, Neil Osheroff2. 1. Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine , Baltimore, Maryland 21205-2185, United States. 2. VA Tennessee Valley Healthcare System , Nashville, Tennessee 37212, United States.
Abstract
Mycobacterium tuberculosis encodes only a single type II topoisomerase, gyrase. As a result, this enzyme likely carries out the cellular functions normally performed by canonical gyrase and topoisomerase IV, both in front of and behind the replication fork. In addition, it is the sole target for quinolone antibacterials in this species. Because quinolone-induced DNA strand breaks generated on positively supercoiled DNA ahead of replication forks and transcription complexes are most likely to result in permanent genomic damage, the actions of M. tuberculosis gyrase on positively supercoiled DNA were investigated. Results indicate that the enzyme acts rapidly on overwound DNA and removes positive supercoils much faster than it introduces negative supercoils into relaxed DNA. Canonical gyrase and topoisomerase IV distinguish supercoil handedness differently during the DNA cleavage reaction: while gyrase maintains lower levels of cleavage complexes on overwound DNA, topoisomerase IV maintains similar levels of cleavage complexes on both over- and underwound substrates. M. tuberculosis gyrase maintained lower levels of cleavage complexes on positively supercoiled DNA in the absence and presence of quinolone-based drugs. By retaining this important feature of canonical gyrase, the dual function M. tuberculosis type II enzyme remains a safe enzyme to act in front of replication forks and transcription complexes. Finally, the N-terminal gate region of the enzyme appears to be necessary to distinguish supercoil handedness during DNA cleavage, suggesting that the capture of the transport segment may influence how gyrase maintains cleavage complexes on substrates with different topological states.
Mycobacterium tuberculosis encodes only a single type II topoisomerase, gyrase. As a result, this enzyme likely carries out the cellular functions normally performed by canonical gyrase and topoisomerase IV, both in front of and behind the replication fork. In addition, it is the sole target for quinolone antibacterials in this species. Because quinolone-induced DNA strand breaks generated on positively supercoiled DNA ahead of replication forks and transcription complexes are most likely to result in permanent genomic damage, the actions of M. tuberculosis gyrase on positively supercoiled DNA were investigated. Results indicate that the enzyme acts rapidly on overwound DNA and removes positive supercoils much faster than it introduces negative supercoils into relaxed DNA. Canonical gyrase and topoisomerase IV distinguish supercoil handedness differently during the DNA cleavage reaction: while gyrase maintains lower levels of cleavage complexes on overwound DNA, topoisomerase IV maintains similar levels of cleavage complexes on both over- and underwound substrates. M. tuberculosis gyrase maintained lower levels of cleavage complexes on positively supercoiled DNA in the absence and presence of quinolone-based drugs. By retaining this important feature of canonical gyrase, the dual function M. tuberculosis type II enzyme remains a safe enzyme to act in front of replication forks and transcription complexes. Finally, the N-terminal gate region of the enzyme appears to be necessary to distinguish supercoil handedness during DNA cleavage, suggesting that the capture of the transport segment may influence how gyrase maintains cleavage complexes on substrates with different topological states.
The vast
majority of bacterial
species encode two type II topoisomerases, topoisomerase IV and gyrase.[1−4] These enzymes function as heterotetramers (GrlA2GrlB2 and ParC2ParE2 for topoisomerase IV
in Gram-positive and Gram-negative species, respectively, and GyrA2GyrB2 for gyrase) and display sequence homology.[1−4] Both enzymes regulate the topological state of DNA by creating a
transient double-stranded break in one segment of DNA (the gate- or
G-segment) and passing a second intact segment (the transport- or
T-segment) through the break.[2,5−7] To maintain genomic integrity during this process, topoisomerase
IV and gyrase covalently attach to the 5′-terminus of each
DNA strand.[2,5−7] This “cleavage
complex” is a hallmark of enzyme activity.[8]Despite this shared catalytic mechanism, differences
in the C-terminal
domains of GrlA/ParC and GyrA confer topoisomerase IV and gyrase with
a unique array of catalytic activities.[3] The C-terminal domain of GrlA/ParC allows topoisomerase IV to interact
with distal DNA segments, which permits it to capture existing intra-
or intermolecular DNA crossovers.[1,4] This property
confers the enzyme with the ability to relax (i.e., remove) positive
or negative DNA supercoils. It also allows the enzyme to remove DNA
knots and tangles in a highly efficient manner.[1,3,4]In contrast, the C-terminal domain
of GyrA wraps DNA, inducing
a positive supercoil between the G- and T-segments.[1,4,9−14] Because these captured DNA segments are proximal to one another,[1,4,15] gyrase greatly favors the catalysis
of intramolecular strand passage reactions. As a result, the enzyme
can efficiently alter superhelical density but is very poor at removing
knots and tangles.[1,4,15,16] Furthermore, because gyrase acts on the
induced positive crossover, it carries out a unidirectional reaction
in the presence of ATP in which it always decreases the DNA linking
number.[1,4,17,18] This allows the enzyme to remove positive, but not
negative, supercoils and to reduce the linking number beyond that
of relaxed DNA. Thus, among all known topoisomerases, gyrase is the
only enzyme able to negatively supercoil DNA.[3,5]As a result of the differences described above, gyrase and topoisomerase
IV play distinct roles during DNA replication and transcription (Figure ).[1,3,19−25] Gyrase removes the positive supercoils that accumulate ahead of
replication forks and goes on to restore the negative superhelicity
of the genome. Although topoisomerase IV can also relax positive supercoils,
its primary function is to remove the precatenanes/catenanes that
are formed behind replication forks, which allows chromosomes to be
segregated appropriately.
Figure 1
Cellular functions of bacterial topoisomerases.
Gyrase removes
positively supercoiled DNA ahead of transcription (top) and replication
(bottom) complexes and in conjunction with topoisomerase I, also maintains
the negative superhelicity of the genome.[1,3,19−25] Topoisomerase IV can remove positive supercoils, but primarily acts
behind the replication fork to resolve precatenanes and unlink daughter
chromosomes. Topoisomerase I acts to remove negative supercoils that
are generated behind transcription complexes. In species that encode
gyrase as the only type II topoisomerase, such as M. tuberculosis, the enzyme likely carries out the functions of both gyrase and
topoisomerase IV and acts ahead of transcription complexes and ahead
of and behind replication forks.[25]
Cellular functions of bacterial topoisomerases.
Gyrase removes
positively supercoiled DNA ahead of transcription (top) and replication
(bottom) complexes and in conjunction with topoisomerase I, also maintains
the negative superhelicity of the genome.[1,3,19−25] Topoisomerase IV can remove positive supercoils, but primarily acts
behind the replication fork to resolve precatenanes and unlink daughter
chromosomes. Topoisomerase I acts to remove negative supercoils that
are generated behind transcription complexes. In species that encode
gyrase as the only type II topoisomerase, such as M. tuberculosis, the enzyme likely carries out the functions of both gyrase and
topoisomerase IV and acts ahead of transcription complexes and ahead
of and behind replication forks.[25]Beyond their essential cellular
functions, both bacterial type
II topoisomerases are targets for quinolone antibacterials, which
kill cells by stabilizing cleavage complexes.[2,7,26,27] As replication
forks, transcription complexes, or other DNA tracking systems encounter
these protein-bound DNA roadblocks, transient cleavage complexes are
converted to nonligatable DNA breaks that induce DNA damage response
pathways. When these pathways are overwhelmed, the DNA breaks result
in cell death. Because quinolone-stabilized cleavage complexes formed
ahead of moving forks and transcription complexes are most likely
to be converted to nonligatable strand breaks, cleavage complexes
stabilized on positively supercoiled DNA are the most dangerous for
the cell. A previous study on type II topoisomerases from Bacillus anthracis and Escherichia coli found that gyrase maintains lower levels of cleavage complexes with
positively (as compared to negatively) supercoiled DNA,[28] making it a safer enzyme to function ahead of
replication forks and transcription complexes.[25] Conversely, topoisomerase IV, which acts behind replication
forks, reportedly maintains levels of cleavage complexes on positively
supercoiled DNA that are similar to[28] or
higher than[29] those generated on negatively
supercoiled molecules.In contrast to the great majority of
bacteria, a few species encode
only a single type II topoisomerase II, gyrase. Among these are several
disease-causing organisms, including Treponema pallidum (syphilis),[30]Helicobacter pylori (stomach and intestinal ulcers),[31]Campylobacter jejuni (gastroenteritis),[32]Mycobacterium leprae (leprosy),[33] and Mycobacterium tuberculosis (tuberculosis).[34] Worldwide, tuberculosis
is one of the top 10 causes of death and ranks above HIV/AIDS as the
leading cause of death due to an infectious disease.[35] Because gyrase is the only type II topoisomerase in M. tuberculosis, it must carry out the activities of both
gyrase and topoisomerase IV.[25] Therefore,
it is functionally distinct from the “canonical” gyrases
found in most species (i.e., species that encode both gyrase and topoisomerase
IV).[36,37] Furthermore, M. tuberculosis gyrase is the sole target for quinolones in this species. Although
the standard treatment regimen for tuberculosis does not typically
include quinolones, the fourth-generation quinolone antibacterials
moxifloxacin and gatifloxacin are critical drugs for treating patients
who have multidrug-resistant tuberculosis or are intolerant of first-line
therapies.[35]Because M. tuberculosis gyrase, a “dual
function” gyrase/topoisomerase IV enzyme,[36,37] is the sole type II topoisomerase and quinolone target in the cell
and because quinolone-induced cleavage complexes formed on positively
supercoiled DNA ahead of replication forks and transcription complexes
are the most dangerous for the cell, we investigated the actions of
this enzyme on overwound DNA. Results indicate that M. tuberculosis gyrase removes positive supercoils much more rapidly than it introduces
negative supercoils into relaxed DNA. Like “canonical”
gyrase, and in contrast to topoisomerase IV, M. tuberculosis gyrase maintains lower levels of cleavage complexes on positively
supercoiled DNA in the absence and presence of quinolone-based drugs.
By retaining this important feature of canonical gyrase, the dual
function M. tuberculosis type II enzyme remains a
safe enzyme to act in front of replication forks and transcription
complexes. Finally, the ability of gyrase to distinguish supercoil
handedness during DNA cleavage is not dependent on elements in the
C-terminal domain of GyrA but appears to require the N-terminal portion
of GyrB.
Materials and Methods
Enzymes and Materials
Full-length M. tuberculosis gyrase subunits (GyrA and GyrB) were expressed
and purified as described
previously.[38] A C-terminally deleted GyrA
mutant (GyrAΔCTD, residues 2–500 of GyrA)
was cloned into a pET28b derivative that added an N-terminal tobacco
etch virus protease (TEV)-cleavable 6xHis tag. The catalytic core
(a fusion of residues 426–675 of GyrB with residues 2–500
of GyrA) was cloned into a pET28b derivative that added N-terminal
TEV-cleavable 6xHis and maltose binding protein tags, as described
previously.[39] Each construct was expressed
and purified as described for the wild-type subunits,[38] except that cells carrying the catalytic core construct
were grown in medium containing 100 μg/mL ampicillin.Negatively supercoiled pBR322 DNA was prepared from E. coli using a Plasmid Mega kit (Qiagen) as described by the manufacturer.
Positively supercoiled pBR322 DNA was prepared by treating negatively
supercoiled molecules with recombinant Archaeoglobus fulgidus reverse gyrase.[40,41] The number of positive supercoils
induced by this process was comparable to the number of negative supercoils
in the original pBR322 preparations.[40] In
all experiments that compared negatively with positively supercoiled
DNA, the negatively supercoiled plasmid preparations were processed
identically to the positively supercoiled molecules except that reaction
mixtures did not contain reverse gyrase. Relaxed pBR322 plasmid DNA
was generated by treating negatively supercoiled pBR322 with calf
thymus topoisomerase I (Invitrogen) and purified as described previously.[42]Ciprofloxacin was obtained from LKT Laboratories,
stored at 4 °C
as a 40 mM stock solution in 0.1 N NaOH, and diluted 5-fold with 10
mM Tris-HCl (pH 7.9) immediately prior to use. Moxifloxacin was obtained
from LKT Laboratories, and levofloxacin was obtained from Sigma-Aldrich.
Both drugs were stored at 4 °C as 20 mM stock solutions in 100%
DMSO. 8-Methyl-moxifloxacin (1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic
acid) and 3′-(AM)P-dione (3-amino-7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-8-methyl-2,4(1H,3H)-quinazolinedione) were generous gifts
from Dr. Robert J. Kerns (University of Iowa). These compounds were
synthesized as reported previously[43,44] and were stored
at 4 °C as 20 mM stock solutions in DMSO. CP-115,953 was the
generous gift of Thomas D. Gootz and Paul R. McGuirk (Pfizer Global
Research), was stored at −20 °C as a 40 mM solution in
0.1 N NaOH, and was diluted 5-fold with 10 mM Tris-HCl (pH 7.9) immediately
prior to use. All other chemicals were analytical reagent grade.
DNA Supercoiling
DNA supercoiling assays were based
on previously published protocols.[38,43] Assays contained
50 nM gyrase (2:1 GyrA/GyrB ratio), 5 nM positively supercoiled or
relaxed pBR322, and 1.5 mM ATP in 20 μL of 10 mM Tris-HCl (pH
7.5), 40 mM KCl, 6 mM MgCl2, 2 mM DTT, 0.1 mg/mL BSA, and
10% glycerol. Reactions were incubated at 37 °C for various times
and stopped by the addition of 3 μL of a mixture of 0.77% SDS
and 77.5 mM Na2EDTA. Samples were mixed with 2 μL
of agarose loading dye [60% sucrose in 10 mM Tris-HCl (pH 7.9), 0.5%
bromophenol blue, and 0.5% xylene cyanol FF] and subjected to electrophoresis
in 1% agarose gels in TBE [100 mM Tris-borate (pH 8.3) and 2 mM EDTA].
Gels were stained with 1 μg/mL ethidium bromide for 30 min.
DNA bands were visualized with medium-range ultraviolet light on an
Alpha Innotech digital imaging system.Alternatively, reaction
products were analyzed by two-dimensional gel electrophoresis as described
previously.[40] The first dimension was run
for 2 h as described in the preceding paragraph. The gel was then
soaked in TBE containing 4.5 μg/mL chloroquine for 2 h with
gentle shaking followed by electrophoresis in the orthogonal direction
(90° clockwise) for 2 h in fresh TBE containing 4.5 μg/mL
chloroquine. Gels were stained and DNA bands were visualized as described
above.
Gyrase-DNA Binding
DNA binding by M. tuberculosis gyrase was monitored by an electrophoretic mobility shift assay.[45] Reactions contained 0–1000 nM gyrase
(3:2 GyrA/GyrB ratio) and 10 nM positively or negatively supercoiled
pBR322 in a total volume of 20 μL of 10 mM Tris-HCl (pH 7.5),
40 mM KCl, 0.1 mg/mL BSA, and 10% glycerol. Reactions were incubated
at 37 °C for 10 min. Samples were mixed with 2 μL of agarose
loading dye and subjected to electrophoresis in 1% agarose gels in
TAE [40 mM Tris-acetate (pH 8.3) and 2 mM Na2EDTA]. Gels
were stained and DNA bands were visualized as described above.
DNA Cleavage
DNA cleavage reactions were based on the
procedure of Aldred et al.[43] Reactions
contained 100 nM wild-type or GyrAΔCTD gyrase (3:2
GyrA/GyrB ratio) or 100 nM catalytic core and 10 nM positively supercoiled,
negatively supercoiled, or relaxed pBR322 in a total volume of 20
μL of 10 mM Tris-HCl (pH 7.5), 40 mM KCl, 6 mM MgCl2, 0.1 mg/mL BSA, and 10% glycerol. Reactions were incubated at 37
°C for 10 min. Enzyme–DNA cleavage complexes were trapped
by adding 2 μL of 5% SDS followed by 2 μL of 250 mM Na2EDTA and 2 μL of 0.8 mg/mL Proteinase K. Reaction mixtures
were incubated at 45 °C for 30 min to digest the enzyme. Samples
were mixed with 2 μL of agarose loading dye and incubated at
45 °C for 2 min before loading on gels. Reaction products were
subjected to electrophoresis in 1% agarose gels in TAE containing
0.5 μg/mL ethidium bromide (except for reactions containing
relaxed DNA, which were run in gels without EtBr and stained with
1 μg/mL EtBr after electrophoresis) and visualized as described
above. DNA cleavage was monitored by the conversion of supercoiled
plasmid to linear molecules and quantified by comparison to a control
reaction in which an equal mass of DNA was digested by EcoRI (New England BioLabs).
Results and Discussion
M. tuberculosis Gyrase Relaxes Positive DNA
Supercoils More Rapidly than It Introduces Negative Supercoils
The sole type II topoisomerase in M. tuberculosis is defined as a gyrase based on its ability to introduce negative
supercoils into relaxed DNA.[36] However,
the enzyme displays a higher decatenation activity than observed in
a canonical gyrase and is therefore a dual function gyrase/topoisomerase
IV enzyme.[36,37] The ability of this enzyme to
supercoil relaxed DNA is well documented,[36−38,46] but no studies have investigated its actions on positively
supercoiled DNA. To determine how this dual function gyrase/topoisomerase
IV type II enzyme interacts with overwound DNA, we assessed the ability
of M. tuberculosis gyrase to relax a positively supercoiled
plasmid and subsequently convert it to a negatively supercoiled molecule.
Enzyme activity was monitored over 45 min in order to observe both
the removal of positive supercoils (the relaxation reaction) and the
introduction of negative supercoils (the supercoiling reaction) within
the same assay.As shown in Figure (top), gyrase rapidly relaxed the overwound
DNA and subsequently introduced negative supercoils much more slowly.
To further investigate the removal of positive supercoils, we monitored
relaxation over a shorter time course (Figure , middle). All of the positive supercoils
appear to be removed by ∼2 min. Conversely, the conversion
of relaxed plasmid to negatively supercoiled DNA took 30–45
min. A similar time course for DNA supercoiling was observed whether
the initial substrate was positively supercoiled (Figure , top) or relaxed (Figure , bottom), highlighting
the distinction between rates of relaxation and supercoiling. This
pattern of activity is similar to that observed for B. anthracis and E. coligyrase.[28] Therefore, like these canonical gyrases, the dual function type
II enzyme from M. tuberculosis functions differently
on positively supercoiled and relaxed DNA.
Figure 2
Gyrase removes positive
supercoils more rapidly than it introduces
negative supercoils into relaxed DNA. Top: Gyrase activity on positively
supercoiled DNA. A time course is shown for the relaxation of positive
supercoils followed by the introduction of negative supercoils. Positively
supercoiled [(+)SC] and negatively supercoiled [(−)SC] standards
are shown. Middle: Expanded time course for the relaxation of (+)SC
DNA by gyrase. Bottom: Time course for the introduction of negative
supercoils into relaxed DNA (Rel) by gyrase. Gel images are representative
of at least three independent experiments.
Gyrase removes positive
supercoils more rapidly than it introduces
negative supercoils into relaxed DNA. Top: Gyrase activity on positively
supercoiled DNA. A time course is shown for the relaxation of positive
supercoils followed by the introduction of negative supercoils. Positively
supercoiled [(+)SC] and negatively supercoiled [(−)SC] standards
are shown. Middle: Expanded time course for the relaxation of (+)SC
DNA by gyrase. Bottom: Time course for the introduction of negative
supercoils into relaxed DNA (Rel) by gyrase. Gel images are representative
of at least three independent experiments.To determine the handedness of the topoisomers in the later
stages
of the relaxation reaction (Figure , middle), reaction products were analyzed by two-dimensional
gel electrophoresis. As shown in Figure , all positive supercoils were removed by
2 min, and negatively supercoiled DNA started to appear between 2
and 3 min. This result confirms the conclusion that the relaxation
of positive supercoils occurs at least 20-fold faster than the introduction
of negative supercoils. However, under the conditions employed, both
of these processes appear to take place in a distributive manner with
the bulk of the DNA moving synchronously through all of the intermediate
topoisomers between the positively supercoiled substrate and the fully
negatively supercoiled product.
Figure 3
Two-dimensional gel analysis of gyrase
activity on positively supercoiled
DNA. The mobility of nicked, positively supercoiled [(+)SC], relaxed
(Rel), and negatively supercoiled [(−)SC] DNA are indicated
in a control gel (top left). DNA products generated after 1 min (top
right), 2 min (bottom left), and 3 min (bottom right) reactions are
shown. Gel images are representative of at least three independent
experiments.
Two-dimensional gel analysis of gyrase
activity on positively supercoiled
DNA. The mobility of nicked, positively supercoiled [(+)SC], relaxed
(Rel), and negatively supercoiled [(−)SC] DNA are indicated
in a control gel (top left). DNA products generated after 1 min (top
right), 2 min (bottom left), and 3 min (bottom right) reactions are
shown. Gel images are representative of at least three independent
experiments.
Gyrase Has a Higher Affinity
for Positively Supercoiled than
Negatively Supercoiled DNA
A previous study found that E. coligyrase displays an ∼10-fold higher affinity
for relaxed over negatively supercoiled DNA.[47] However, binding interactions with positively supercoiled molecules
have yet to be assessed for gyrase. Because M. tuberculosis gyrase carries out distributive reactions for both the removal of
positive supercoils and the introduction of negative supercoils, we
determined whether the differences in reaction rates reflect differences
in enzyme affinity for positively and negatively supercoiled DNA.
An electrophoretic mobility shift assay was employed to assess the
relative affinities of gyrase for positively or negatively supercoiled
molecules. As shown in Figure , gyrase induced much greater shifts with positively supercoiled
DNA than negatively supercoiled molecules and did so at lower enzyme
concentrations. The nicked DNA in these gels served as an internal
control for molecules that were not under torsional stress. In the
presence of positively supercoiled DNA, gyrase did not substantially
shift the nicked/relaxed molecules, suggesting that the enzyme has
a significantly higher affinity for the positively supercoiled plasmid.
In contrast, in incubations with negatively supercoiled DNA, gyrase
preferentially shifted the nicked plasmid and altered its mobility
to a much greater extent than it did with the negatively supercoiled
molecules. Thus, gyrase appears to have a higher affinity for positively
supercoiled DNA than negatively supercoiled DNA and has an intermediate
affinity for DNA molecules that lack torsional stress. This pattern
is consistent with positively supercoiled DNA being the preferred
substrate for gyrase-catalyzed DNA strand passage, with relaxed DNA
as an intermediary product and negatively supercoiled DNA as the final
reaction product.
Figure 4
Gyrase preferentially binds positively supercoiled DNA.
The electrophoretic
mobility shifts of positively supercoiled [(+)SC), top] and negatively
supercoiled [(−)SC, bottom] DNA induced by increasing concentrations
of gyrase are shown. Original positions of nicked, (+)SC, and (−)SC
DNA are indicated. Gel images are representative of at least three
independent experiments.
Gyrase preferentially binds positively supercoiled DNA.
The electrophoretic
mobility shifts of positively supercoiled [(+)SC), top] and negatively
supercoiled [(−)SC, bottom] DNA induced by increasing concentrations
of gyrase are shown. Original positions of nicked, (+)SC, and (−)SC
DNA are indicated. Gel images are representative of at least three
independent experiments.
Gyrase Maintains Lower Levels of Cleavage Complexes with Positively
Supercoiled DNA
The cleavage complexes that are most dangerous
for the cell are those that are formed on overwound DNA ahead of moving
tracking systems. Previous studies indicate that gyrase and topoisomerase
IV differ in their ability to recognize DNA geometry while they are
cleaving the double helix.[28,29] This specificity may
be related to the position of each enzyme relative to replication
forks and transcription complexes.[1,3,19−25] Canonical gyrase, which functions ahead of these tracking systems,
often works on overwound DNA and has the potential to create dangerous
cleavage complexes. Consistent with this function, gyrase maintains
lower levels of cleavage complexes on positively supercoiled DNA.[28] In contrast, topoisomerase IV works primarily
behind replication forks and is less likely to encounter moving DNA
tracking systems. Thus, it does not distinguish between overwound
and underwound DNA during cleavage (or actually maintains higher levels
of cleavage complexes with positively supercoiled substrates).[28,29]As a dual function enzyme, M. tuberculosis gyrase must be able to work both ahead of and behind the replication
fork and other DNA tracking systems and could conceivably distinguish
supercoil handedness during DNA cleavage as a gyrase or as a topoisomerase
IV. To address this issue, the ability of M. tuberculosis gyrase to cleave positively and negatively supercoiled DNA was determined.
Like canonical gyrase,[28]M. tuberculosis gyrase maintained ∼3-fold lower levels of cleavage complexes
on overwound compared to underwound DNA in the absence of drugs (Figure ). This discrimination
is despite the fact that the enzyme displays a higher affinity for
positively supercoiled molecules and suggests that M. tuberculosis gyrase cycles through the DNA cleavage reaction more rapidly on
positively supercoiled substrates.
Figure 5
Gyrase maintains lower levels of cleavage
complexes on positively
supercoiled DNA in the absence of drugs. Levels of cleavage complexes
generated by varying concentrations of gyrase on positively supercoiled
[(+)SC DNA, red] or negatively supercoiled [(−)SC DNA, blue]
are shown. Error bars represent the standard deviations for at least
three independent experiments.
Gyrase maintains lower levels of cleavage
complexes on positively
supercoiled DNA in the absence of drugs. Levels of cleavage complexes
generated by varying concentrations of gyrase on positively supercoiled
[(+)SC DNA, red] or negatively supercoiled [(−)SC DNA, blue]
are shown. Error bars represent the standard deviations for at least
three independent experiments.Because quinolones stabilize cleavage complexes and are clinically
important drugs for the treatment of tuberculosis, we also monitored
cleavage complexes generated by gyrase in the presence of moxifloxacin
(Figure ). Similar
to the results seen in the absence of drugs, gyrase maintained ∼3-fold
lower levels of cleavage complexes on positively supercoiled molecules.
Levels of cleavage complexes generated by the enzyme on relaxed DNA
were between those generated on positively and negatively supercoiled
plasmid. Gyrase also maintained the distinction between over and underwound
DNA in the presence of ciprofloxacin or levofloxacin, two other clinically
relevant quinolones; CP-115,953, a quinolone that displays high activity
against both bacterial and eukaryotic type II topoisomerases;[48−51] and two quinolone-derived drugs, 8-methyl-moxifloxacin and 3′-(AM)P-dione,
which overcome quinolone resistance caused by mutations in M. tuberculosis gyrase[38,39] (Figure ). These results
suggest that, although gyrase in M. tuberculosis has
adapted to perform some of the functions of topoisomerase IV, it still
retains the characteristics that make gyrase a safe enzyme to function
ahead of replication forks and other DNA tracking systems such as
RNA polymerase.
Figure 6
Gyrase maintains lower levels of cleavage complexes on
positively
supercoiled DNA in the presence of moxifloxacin. Left: Levels of cleavage
complexes generated by gyrase on positively supercoiled [(+)SC DNA,
red], relaxed (Rel, green), or negatively supercoiled [(−)SC
DNA, blue] in the presence of the quinolone moxifloxacin. Error bars
represent the standard deviations for at least three independent experiments.
Right: Representative gels of DNA cleavage induced by gyrase on negatively
supercoiled [(−)SC, top], relaxed (Rel, middle), or positively
supercoiled [(+)SC, bottom] DNA in the presence of moxifloxacin. DNA
controls in the absence of enzyme (DC) and DNA digested by EcoRI (EcoRI) are shown. The positions
of nicked, relaxed, linear, and supercoiled DNA are indicated.
Figure 7
Gyrase maintains lower levels of cleavage complexes
on positively
supercoiled DNA in the presence of ciprofloxacin, levofloxacin, and
other quinolone-derived compounds. Left: Levels of cleavage complexes
generated by gyrase on positively supercoiled [(+)SC DNA, red] or
negatively supercoiled [(−)SC DNA, blue] in the presence of
ciprofloxacin. Right: Levels of cleavage complexes generated by gyrase
on positively supercoiled [(+)SC DNA, red] or negatively supercoiled
[(−)SC DNA, blue] in the presence of levofloxacin (Levo, 100
μM), CP-115,953 (953, 100 μM), 8-methyl-moxifloxacin (Me-Moxi,
20 μM), and 3′-(AM)P-dione (dione, 20 μM). Error
bars represent the standard deviations for at least three independent
experiments.
Gyrase maintains lower levels of cleavage complexes on
positively
supercoiled DNA in the presence of moxifloxacin. Left: Levels of cleavage
complexes generated by gyrase on positively supercoiled [(+)SC DNA,
red], relaxed (Rel, green), or negatively supercoiled [(−)SC
DNA, blue] in the presence of the quinolonemoxifloxacin. Error bars
represent the standard deviations for at least three independent experiments.
Right: Representative gels of DNA cleavage induced by gyrase on negatively
supercoiled [(−)SC, top], relaxed (Rel, middle), or positively
supercoiled [(+)SC, bottom] DNA in the presence of moxifloxacin. DNA
controls in the absence of enzyme (DC) and DNA digested by EcoRI (EcoRI) are shown. The positions
of nicked, relaxed, linear, and supercoiled DNA are indicated.Gyrase maintains lower levels of cleavage complexes
on positively
supercoiled DNA in the presence of ciprofloxacin, levofloxacin, and
other quinolone-derived compounds. Left: Levels of cleavage complexes
generated by gyrase on positively supercoiled [(+)SC DNA, red] or
negatively supercoiled [(−)SC DNA, blue] in the presence of
ciprofloxacin. Right: Levels of cleavage complexes generated by gyrase
on positively supercoiled [(+)SC DNA, red] or negatively supercoiled
[(−)SC DNA, blue] in the presence of levofloxacin (Levo, 100
μM), CP-115,953 (953, 100 μM), 8-methyl-moxifloxacin (Me-Moxi,
20 μM), and 3′-(AM)P-dione (dione, 20 μM). Error
bars represent the standard deviations for at least three independent
experiments.
Recognition of Supercoil
Geometry During Cleavage Is Not Dependent
on the C-Terminal Domain of GyrA but Does Require the N-Terminal Portion
of GyrB
A previous study with E. coligyrase
demonstrated that removal of the entire C-terminal domain (CTD) of
GyrA converted gyrase to a “conventional” type II topoisomerase.[12] The enzyme was no longer able to introduce negative
supercoils into relaxed DNA but, like topoisomerase IV, gained the
ability to relax negatively supercoiled DNA in the presence of ATP
and exhibited a higher decatenation activity than the parent enzyme.
However, the effects of this alteration on DNA cleavage have not been
examined. For human topoisomerase IIα, removal of the CTD does
not change the ability of the enzyme to discern supercoil handedness
during cleavage.[52] To determine the role
of the CTD in DNA geometry recognition by a bacterial enzyme during
cleavage, we monitored the ability of M. tuberculosis gyrase that contained wild-type GyrB and a mutant GyrA in which
the CTD was deleted (GyrAΔCTD gyrase, which contains
residues 2–500 of GyrA) to cleave over- and underwound DNA
substrates (Figure ). GyrAΔCTD gyrase still maintained lower levels
of cleavage complexes with positively supercoiled DNA. Therefore,
like the human enzyme, the ability of M. tuberculosis gyrase to distinguish supercoil handedness during the cleavage reaction
does not rely on the CTD.
Figure 8
GyrAΔCTD gyrase maintains lower
levels of cleavage
complexes on positively supercoiled DNA. Left: Levels of cleavage
complexes generated by varying concentrations of GyrAΔCTD gyrase on positively supercoiled [(+)SC, red] or negatively supercoiled
[(−)SC, blue] DNA in the absence of quinolones. Right: Levels
of cleavage complexes generated by GyrAΔCTD gyrase
on positively supercoiled [(+)SC, red] or negatively supercoiled [(−)SC,
blue] DNA in the presence of moxifloxacin. Error bars represent the
standard deviations for at least three independent experiments.
GyrAΔCTD gyrase maintains lower
levels of cleavage
complexes on positively supercoiled DNA. Left: Levels of cleavage
complexes generated by varying concentrations of GyrAΔCTD gyrase on positively supercoiled [(+)SC, red] or negatively supercoiled
[(−)SC, blue] DNA in the absence of quinolones. Right: Levels
of cleavage complexes generated by GyrAΔCTD gyrase
on positively supercoiled [(+)SC, red] or negatively supercoiled [(−)SC,
blue] DNA in the presence of moxifloxacin. Error bars represent the
standard deviations for at least three independent experiments.It is not obvious which portion
of M. tuberculosis gyrase is responsible for the
recognition of DNA geometry during
cleavage. Although DNA scission occurs within the catalytic core of
the enzyme (defined as residues 426–675 of GyrB and residues
2–500 of GyrA), the N-terminal gate region (residues 2–425
of GyrB) is crucial for capturing the T-segment.[53−55] The N-terminal
gate in eukaryotic type II topoisomerases is also important for capturing
the T-segment[56] and changes within this
region have been shown to modulate rates of DNA cleavage.[57,58] Therefore, this region of M. tuberculosis gyrase
could have an important role in distinguishing supercoil handedness.
Previous work with the catalytic core of human topoisomerase IIα
showed that the N-terminal gate was not required for the recognition
of supercoil geometry during cleavage.[56] To determine if this was also the case for the bacterial type II
topoisomerase, we evaluated the ability of the catalytic core of M. tuberculosis to cleave positively and negatively supercoiled
DNA (Figure ). Unlike
full-length or GyrAΔCTD gyrase, the catalytic core
did not distinguish between overwound and underwound DNA and maintained
similar levels of cleavage complexes on both substrates in the absence
or presence of moxifloxacin. Therefore, the ability of M.
tuberculosis gyrase to recognize DNA geometry during cleavage
appears to be embedded, at least in part, in the N-terminal region
of the enzyme.
Figure 9
Catalytic core of gyrase maintains similar levels of cleavage
complexes
on positively and negatively supercoiled DNA. Left: Levels of cleavage
complexes generated by varying concentrations of the catalytic core
on positively supercoiled [(+)SC, red] or negatively supercoiled [(−)SC,
blue] DNA in the absence of quinolones. Right: Levels of cleavage
complexes generated by the catalytic core on positively supercoiled
[(+)SC, red] or negatively supercoiled [(−)SC, blue] DNA in
the presence of moxifloxacin. Error bars represent the standard deviations
for at least three independent experiments.
Catalytic core of gyrase maintains similar levels of cleavage
complexes
on positively and negatively supercoiled DNA. Left: Levels of cleavage
complexes generated by varying concentrations of the catalytic core
on positively supercoiled [(+)SC, red] or negatively supercoiled [(−)SC,
blue] DNA in the absence of quinolones. Right: Levels of cleavage
complexes generated by the catalytic core on positively supercoiled
[(+)SC, red] or negatively supercoiled [(−)SC, blue] DNA in
the presence of moxifloxacin. Error bars represent the standard deviations
for at least three independent experiments.
Conclusions
Gyrase from M. tuberculosis and other species
encoding a single type II topoisomerase must carry out the functions
usually associated with topoisomerase IV. Thus, gyrase from these
species has a mix of characteristics from canonical gyrases (ability
to induce negative supercoils into DNA) and topoisomerase IV (ability
to decatenate DNA).[36,37] Our results indicate that the
dual function M. tuberculosis gyrase retains features
of canonical gyrase that make it a safer enzyme to function ahead
of moving DNA tracking systems. In particular, it is able to rapidly
remove positive supercoils, while its introduction of negative supercoils
occurs more slowly. Furthermore, it is able to distinguish between
positively and negatively supercoiled DNA during the cleavage reaction
and maintains significantly lower levels of cleavage complexes on
overwound DNA. The N-terminal gate region of the enzyme is required
to distinguish supercoil handedness, suggesting that the capture of
the transport segment may influence how gyrase maintains cleavage
complexes on substrates with different topological states. The involvement
of the N-terminal region in geometry recognition also points to a
mechanistic difference between M. tuberculosis gyrase
and human topoisomerase IIα,[56] implying
that bacterial and eukaryotic topoisomerases may utilize distinct
methods for sensing the supercoil geometry of their substrates.
Authors: J F Tomb; O White; A R Kerlavage; R A Clayton; G G Sutton; R D Fleischmann; K A Ketchum; H P Klenk; S Gill; B A Dougherty; K Nelson; J Quackenbush; L Zhou; E F Kirkness; S Peterson; B Loftus; D Richardson; R Dodson; H G Khalak; A Glodek; K McKenney; L M Fitzegerald; N Lee; M D Adams; E K Hickey; D E Berg; J D Gocayne; T R Utterback; J D Peterson; J M Kelley; M D Cotton; J M Weidman; C Fujii; C Bowman; L Watthey; E Wallin; W S Hayes; M Borodovsky; P D Karp; H O Smith; C M Fraser; J C Venter Journal: Nature Date: 1997-08-07 Impact factor: 49.962
Authors: Katie J Aldred; Tim R Blower; Robert J Kerns; James M Berger; Neil Osheroff Journal: Proc Natl Acad Sci U S A Date: 2016-01-20 Impact factor: 11.205
Authors: S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell Journal: Nature Date: 1998-06-11 Impact factor: 49.962
Authors: Elizabeth G Gibson; Tim R Blower; Monica Cacho; Ben Bax; James M Berger; Neil Osheroff Journal: ACS Infect Dis Date: 2018-05-17 Impact factor: 5.084